Fundraising FoxOphidion
Bethlehem, US · 3 known investors
Find your way into Ophidion
Each arrow is one introduction. Sign up to fill in the first one.
18 people can intro you to Julie
Ask Christopher Marshall to introduce you to Julie Miwa
You →Christopher · together at Ophidion →Julie
Sign up to find every way you can get introduced to Ophidion
- Your email: who you already know at Ophidion, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Ophidion team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Ophidion is an early-stage CNS biopharmaceutical company developing a non-invasive carrier technology that delivers gene-silencing agents and other therapeutics across the blood-brain barrier into the brain. It is building a pipeline of disease-modifying and symptomatic treatments for neurodegenerative diseases, including Huntington's disease and cognition-related conditions.
Founders & leadership
JM
Julie MiwaFounderJulie Miwa is a translational neuroscientist with expertise in nicotinic receptor biology, now serving as Director and Promoter of Ophidion, an early-stage biopharmaceutical company developing gene-silencing therapeutics for neurodegenerative diseases.
YH
Yacoub HabibNamed on SEC filing
Board
ML
Michael LarkBoard director
SF
Scott FishmanBoard director
CB
Claudine BruckBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$4M disclosed across 3 rounds · 2019–2024
▶$655.2KraisedOct 2024 · 8 investors · PharmaceuticalsRule 506(b)
▶$655.2KraisedOct 2024 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael LarkDirector
- Yacoub HabibExecutive Officer, Director, Promoter
- Julie MiwaDirector, Promoter
- Scott FishmanDirector
- Claudine BruckDirector
- Offering amount
- $1.2M
- Amount sold
- $655.2K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedSep 2023 · 8 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedSep 2023 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Julie MiwaDirector, Promoter
- Michael W. LarkDirector
- Scott FishmanDirector
- Claudine BruckDirector
- Yacoub HabibExecutive Officer, Promoter
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedJan 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$1.7MraisedJan 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Yacoub HabibExecutive Officer, Promoter
- Julie MiwaDirector, Promoter
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Esperion TherapeuticsBiopharma developing HDL-C regulating therapies; listed 2000.
Alexion PharmaceuticalsAlexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Viridian TherapeuticsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Maxion TherapeuticsMaxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs. It focuses on first-in-class and best-in-class treatments for diseases driven by ion channel and GPCR dysfunction, including pain, autoimmune and cardiovascular conditions.
Vividion TherapeuticsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
Companies working in the same space as Ophidion.
Frequently asked questions
- What does Ophidion do?
- Ophidion is an early-stage CNS biopharmaceutical company developing a non-invasive carrier technology that delivers gene-silencing agents and other therapeutics across the blood-brain barrier into the brain. It is building a pipeline of disease-modifying and symptomatic treatments for neurodegenerative diseases, including Huntington's disease and cognition-related conditions.
- Who founded Ophidion?
- Ophidion was founded by Julie Miwa.
- Who are Ophidion's investors?
- Ophidion's investors include Delaware Crossing Investor Group, Eisai Innovation, Inc., Robin Hood Ventures.
- How much funding has Ophidion raised?
- Ophidion has disclosed $4M raised across 3 rounds.
- Where is Ophidion headquartered?
- Ophidion is headquartered in Bethlehem, US.